文献速递糖尿病

卡格列净对2型糖尿病截肢风险的影响:CANVAS项目分析

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
PubMed 文献 · Diabetologia · 2019-03-12

CANVAS项目二次分析显示,卡格列净增加2型糖尿病高危患者下肢截肢风险(6.30 vs 3.37/1000人年,HR 1.97),以轻微截肢为主,缺血与感染病因及100mg与300mg剂量风险相似,但未明确特定机制或高危亚组。

要点

  • 卡格列净增加截肢风险,主要为轻微截肢,需警惕。
  • 既往截肢史是截肢最强预测因素,HR 21.31。
  • 各亚组截肢事件数均少于避免的主要心血管不良事件数。

核心结论

  • 卡格列净增加2型糖尿病高危患者截肢风险,以轻微截肢为主,未发现特定病因机制或高危亚组。

研究设计与样本

  • CANVAS项目的二次分析,比较卡格列净与安慰剂对截肢风险的影响。

主要发现

  • 截肢发生率为6.30 vs 3.37/1000人年(卡格列净 vs 安慰剂),HR 1.97(95%CI 1.41, 2.75)。
  • 187例(1.8%)发生非创伤性下肢截肢,轻微占71%,主要占29%。
  • 缺血与感染病因及100mg与300mg剂量间风险相似。
  • 既往截肢史与截肢风险强相关(HR 21.31,95%CI 15.40, 29.49)。

临床怎么用

  • 对高心血管风险的2型糖尿病患者使用卡格列净时,应评估截肢危险因素,尤其既往截肢史。

局限性

  • 为二次分析,未发现特定机制或高危亚组,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The primary analysis of the Canagliflozin cardioVascular Assessment Study (CANVAS) Program showed canagliflozin to have a beneficial effect on cardiovascular and renal outcomes in people with type 2 diabetes at high cardiovascular risk, but also an unexpected increased risk of major or minor lower extremity amputation. These secondary analyses explore this finding in more detail. METHODS: The effect of canagliflozin on amputation risk in the CANVAS Program was calculated for amputations of different types and proximate aetiologies and different canagliflozin doses. Univariate and multivariate associations of baseline characteristics with amputation risk were determined and proportional and absolute effects of canagliflozin were compared across subgroups. RESULTS: There were 187 (1.8%) participants with atraumatic lower extremity amputations (minor 71%, major 29%); as previously published, rates were 6.30 vs 3.37 per 1000 participant-years with canagliflozin vs placebo (HR 1.97 [95% CI 1.41, 2.75]). Risk was similar for ischaemic and infective aetiologies and for 100 mg and 300 mg doses. Overall amputation risk was strongly associated with baseline history of prior amputation (major or minor) (HR 21.31 [95% CI 15.40, 29.49]) and other established risk factors. No interactions between randomised treatment and participant characteristics explained the effect of canagliflozin on amputation risk. For every clinical subgroup studied, numbers of amputation events projected were smaller than numbers of major adverse cardiovascular events averted. CONCLUSIONS/INTERPRETATION: The CANVAS Program demonstrated that canagliflozin increased the risk of amputation (mainly minor) in this study population. Anticipated risk factors for amputation were identified, such as prior history of amputation, peripheral vascular disease and neuropathy, but no specific aetiological mechanism or at-risk subgroup for canagliflozin was identified.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Matthews DR, Li Q, Perkovic V, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia. 2019. PMID: 30868176. doi:10.1007/s00125-019-4839-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。